F. Jiang

发表

Small molecule activation of PKM2 in cancer cells induces serine auxotrophy.

L. Cantley, C. Kung, J. Hixon, 2012, Chemistry & biology.

Structural insights into PROTAC-mediated degradation of Bcl-xL.

F. Jiang, C. Chung, J. Harling, 2020, ACS chemical biology.

Crystallographic structure of a small molecule SIRT1 activator-enzyme complex

F. Jiang, Beth L. Pietrak, T. Riera, 2014, Nature Communications.

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Hua Yang, Fang Wang, Zenon Konteatis, 2017, Cancer discovery.

Targeting AML-associated FLT3 mutations with a type I kinase inhibitor.

F. Jiang, A. Wang, J. Perentesis, 2020, The Journal of clinical investigation.

Synthesis of carba-NAD and the structures of its ternary complexes with SIRT3 and SIRT5.

F. Jiang, C. Mao, R. Perni, 2012, The Journal of organic chemistry.

Full-length human glutaminase in complex with an allosteric inhibitor.

Abhishek K. Jha, S. Gross, B. Delabarre, 2011, Biochemistry.

Synthesis and Biological Evaluation of 3′,5′‐d 2 ‐Cannabidiol

F. Jiang, Wei Zhang, Ping Wu, 2023, ChemistrySelect.

Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion.

K. Marks, S. Gross, B. Delabarre, 2021, Journal of medicinal chemistry.

Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.

Melinda M. Mulvihill, R. Rowntree, Wentao Wei, 2021, Journal of medicinal chemistry.

lncRNA ZFPM2‐AS1 promotes proliferation via miR‐18b‐5p/VMA21 axis in lung adenocarcinoma

F. Jiang, M. Xue, Weimin Tao, 2020, Journal of cellular biochemistry.